AptarGroup (ATR) Margin Compression Challenges Bullish Pharma Growth Narrative In Q1 2026

AptarGroup (ATR) opened 2026 with Q1 revenue of US$982.9 million and basic EPS of US$1.13, while trailing twelve month revenue stood at US$3.9 billion and EPS at US$5.93, setting a clear benchmark for the latest quarter against its recent run rate. Over the past five reported quarters, revenue has moved from US$887.3 million in Q1 2025 to US$982.9 million in Q1 2026, with quarterly EPS ranging between US$1.13 and US$1.95 over that stretch. This gives investors a consistent view of how the top and bottom lines have tracked together. With a current net margin of 10%, these results frame a business that is monetizing its revenue base efficiently enough to keep profitability firmly in focus as a key part of the earnings story.

See our full analysis for AptarGroup.

With the headline numbers set, the next step is to see how this earnings print lines up with the main narratives around AptarGroup, highlighting where the story is backed by the data and where expectations might need a reset.

See what the community is saying about AptarGroup

TTM earnings growth of 4.4% keeps profit story intact

• Over the last twelve months, net income excluding extra items was US$386.7 million on US$3.9b of revenue, with earnings up 4.4% year over year and revenue growth at 5.3% annually.
• Supporters of the bullish view argue that AptarGroup’s focus on higher value drug delivery platforms can lift profitability, and the recent numbers partly line up with that story:
  • Trailing twelve month EPS sits at US$5.93 compared with quarterly EPS that has ranged between US$1.13 and US$1.95 in the last five reported quarters, which points to a business generating consistent profits even as individual quarters move around.
  • Net income over the last year of US$386.7 million and a 10% net margin give bulls a solid starting point for their thesis that margin expansion from premium pharma products could be additive if that segment grows as expected.

Bulls point to pharma and sustainability themes as long term growth engines, and this steady profit base is exactly what they build their case on 🐂 AptarGroup Bull Case

10% margin edges lower against 10.4% prior level

• Net margin is currently 10%, slightly below last year’s 10.4%, with trailing revenue at US$3.9b and trailing net income at US$386.7 million, so profitability is solid but a touch softer than the prior period.
• Skeptics focus on this small margin slip as a sign that cost pressures and mix shifts are biting, and the reported figures give some support to that cautious angle:
  • Quarterly net income excluding extra items moved from US$78.8 million in Q1 2025 to US$72.7 million in Q1 2026, even as quarterly revenue rose from US$887.3 million to US$982.9 million, which fits the bearish concern that higher costs and product mix can squeeze the bottom line.
  • The margin dip from 10.4% to 10% sits alongside commentary about legal and sustainability related spending, so bears can reasonably point to these 4 basis points of margin compression as evidence that extra costs are already flowing through.

Bears argue that even modest margin compression matters when the company is already spending heavily on R&D, legal defense and sustainability, and the 10% margin line shows that those costs are visible in the numbers 🐻 AptarGroup Bear Case

P/E of 19.6x sits above peers as DCF fair value signals US$178.59

• At a current share price of US$119.02, the stock trades on a 19.6x P/E compared with a global packaging industry average of 15.6x and a peer average of 17.3x, while the DCF fair value in the data is US$178.59 and the single allowed analyst price target is US$163.14.
• The balanced narrative suggests the market is already paying up for quality and growth, and the figures make that tension quite clear:
  • The P/E premium over both industry and peers, combined with trailing earnings growth of 4.4% and revenue growth of 5.3%, fits the idea that investors are pricing in more than just the recent growth run rate.
  • At the same time, a DCF fair value of US$178.59 and an analyst target of US$163.14 both sit above the current US$119.02 share price, which lines up with analysts’ view that the current multiple could still be reasonable if AptarGroup delivers on its earnings plans.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for AptarGroup on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Seeing both optimism and caution in the numbers, it makes sense to move fast and test the story against the data yourself with 5 key rewards and 2 important warning signs

See What Else Is Out There

Margin compression from 10.4% to 10% alongside Q1 net income drifting lower even as revenue rises shows earnings quality is under pressure.

If you are concerned that this kind of squeeze could hurt long term compounding, it is worth checking companies filtered by 67 resilient stocks with low risk scores for steadier profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com